Table 1.
Characteristic of patients with hematologic malignancies and past or chronic HBV infection receiving Bruton tyrosine kinase inhibitor therapy without antiviral prophylaxis (N=29)
| Characteristic | Total (N=29) |
Ibrutinib (N=13) |
Acalabrutinib (N=15) |
Zanubrutinib (N=1) |
|---|---|---|---|---|
| Age, median (IQR), years | 72 (67 - 79) | 76 (71 - 82) | 71 (66 - 76) | 66 |
| Sex | ||||
| Male | 19 | 8 | 10 | 1 |
| Female | 10 | 5 | 5 | 0 |
| Race and ethnicity | ||||
| White | 21 | 10 | 10 | 1 |
| Black or African American | 4 | 3 | 1 | 0 |
| Hispanic or Latino | 4 | 0 | 4 | 0 |
| Hematologic malignancy | ||||
| Chronic lymphocytic leukemia | 22 | 12 | 9 | 1 |
| Mantle cell lymphoma | 6 | 0 | 6 | 0 |
| Marginal zone lymphoma | 1 | 1 | 0 | 0 |
| Waldenstrom macroglobulinemia | 0 | 0 | 0 | 0 |
| Type of HBV infection | ||||
| Past | 28 | 13 | 14 | 1 |
| Chronic | 1 | 0 | 1 | 0 |
| HBsAg, median (IQR), IU/L | 101 (6 - 231) | 137 (13 - 231) | 0 (0 - 214) | 204 |
| HBV reactivation | 3 | 1 | 2 | 0 |
| BTK inhibitors as first line of therapy | 9 | 7 | 2 | 0 |
| Duration of BTK inhibitors therapy, median (IQR), months | 25 (8 - 47) | 30 (3 - 50) | 14 (11 - 37) | 51 |
| Cumulative BTK inhibitors dose, median (IQR), mg | N/A | 218,400 (42,000 - 420,000) | 84,000 (66,000 -222,000) | 244,800 |
| Follow-up period, median (IQR), months | 25 (8 - 43) | 48 (5-67) | 21 (15 - 45) | 81 |
Abbreviations: BTK, Bruton tyrosine kinase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IQR, interquartile range; N/A, not applicable.